Вердай (Indocyanine Green) is utilized across various clinical domains where physiological information or real-time visualization is required for patient management. As a fluorescent diagnostic dye, its function is to facilitate the assessment of underlying functional or anatomical conditions.

The agent is primarily applied for ophthalmic angiography, the assessment of liver excretory capacity, the measurement of cardiac output, and fluorescence-guided visualization in surgery, particularly when assessing organ-specific functional status.

Uses and Benefits by Clinical Scenario

The medication is used in scenarios requiring visualization for surgical precision, such as the delineation of tumor borders or confirming tissue perfusion during reconstructive procedures. By providing quantifiable data in cases such as chronic liver disease, it aids in the evaluation of appropriate clinical strategies. In ophthalmology, it is used to identify issues in the deep microvasculature of the eye that may be associated with visual disturbances.

“The clarity gained from this specialized imaging technique offers supportive insight for complex anomalies.”

Quick Fact: Supports Clarity for Treatment Direction

This section outlines the official eligibility and exclusion criteria for Вердай (Vorasidenib/Voranigo), strictly based on governmental regulatory documents (e.g., FDA, MHRA, EMA). This information does not constitute medical advice.

Eligibility Scope

Category	Regulatory Requirement or Restriction
Populations Allowed	Adults and pediatric patients 12 years of age and older.
Genetic Requirement	Must have Grade 2 Astrocytoma or Oligodendroglioma with a susceptible IDH1 or IDH2 mutation (as detected by an approved test).
Prior Treatment	Must follow surgery (biopsy, sub-total, or gross total resection).
Contraindicated	No absolute contraindications are listed in the Prescribing Information.

---

Special Population Restrictions

• Pregnancy and Fetal Risk: The drug can cause fetal harm. Females of reproductive potential must use effective nonhormonal contraception during treatment and for 3 months after the last dose. Hormonal contraceptives may be ineffective. Males with female partners of reproductive potential must also use effective contraception.
• Lactation: Women should not breastfeed during treatment and for 2 months following the last dose.
• Age Restriction: Safety and effectiveness have not been established in pediatric patients less than 12 years of age.
• Organ Function: Use in patients with severe hepatic impairment or severe renal impairment (CrCl leq40 mL/min) has not been adequately studied, and special caution or monitoring is typically required.

The regulatory profile thus defines a highly specific eligible patient population based on age, tumor type, and genetic mutation status, while establishing strict reproductive constraints due to potential embryo-fetal toxicity and impaired fertility warnings.

Official Interaction Profile

The official interaction profile for this product is documented across several domains, primarily focusing on its pharmacokinetic disposition (absorption and clearance) and potential interference with diagnostic tests.

Interactions Affecting Drug Exposure

Concomitant use with certain medicinal products can alter the plasma levels of this product. Specific interactions are noted based on their effect on the liver and biliary secretion or absorption in the blood:

• Clearance-Altering Substances: Medicinal products that interfere with liver function may alter the clearance rate of this product. For instance, Probenecid and its metabolites are documented to depress the biliary secretion of the product, which can affect liver function test results.
• Absorption-Altering Substances: The absorption peak of the product in blood is reduced by injectables containing sodium bisulphite. Medicinal products such as anticonvulsants, opium alkaloids, phenobarbital, and phenylbutazone are also listed as substances that can reduce absorption.

Procedural and Diagnostic Interference

Specific constraints regarding administration and diagnostic testing are included in the regulatory documentation:

• Mixing Restrictions: In the absence of specific compatibility data, the product must not be mixed with other medicinal products.
• Sample Collection Constraint: Heparin preparations that contain sodium bisulphite should not be used as an anticoagulant when collecting samples for analysis, due to the risk of reduced absorption.
• Thyroid Test Interference: The iodine content of the product may interfere with thyroid function tests. Radioactive iodine uptake studies should be deferred for at least one week following administration.

How Вердай Works: Mechanism of Action

Targeting Local Inflammation via Selective Enzyme Inhibition

This core mechanism involves the drug acting as a selective inhibitor of the Cyclooxygenase-2 (COX-2) enzyme. This action prevents the production of inflammatory Prostaglandins at the site of injury, which effectively modifies the early molecular steps of the inflammatory cascade and alters the local fluid dynamics and tissue permeability related to the inflammatory response and tissue sensitization to nociception.

Modulating Pain Signal Transmission in Neural Pathways

The secondary mechanistic domain engages the Nociceptin/Orphanin FQ (NOP) receptor system, influencing the regulation of processes driven by distinct signaling patterns in the central and peripheral nervous systems. By modulating NOP receptors, the drug adjusts the release of neurotransmitters involved in transmitting pain, which modulates the downstream signaling intensity of afferent pain pathways and influences the systemic physiological response to nociceptive input.

Вердай (Indocyanine Green or ICG) is an injectable diagnostic agent whose administration is conducted according to procedure-specific protocols. Its primary use is in acute, monitored settings. The routes of administration are mainly Intravenous (IV) injection, though Interstitial or Intradermal routes may be employed for specialized procedures like lymphatic mapping.

Preparation and Dosing

The medication is supplied as a lyophilized powder and is reconstituted with Sterile Water for Injection, USP. This preparation adheres to specific parameters, including administration of the solution within 6 hours of mixing to maintain stability and accuracy. The dose is determined by the specific diagnostic task. For example, assessing hepatic function involves a dose of 0.5 mg/kg body weight, while ophthalmic angiography may utilize doses up to 40 mg. For any indication, the total administered dose does not exceed 2 mg/kg body weight.

Administration Technique and Timing

The IV injection is executed as a tight bolus, a rapid injection technique designed for measurement of circulatory dynamics, and is followed by a saline flush (e.g., 10 mL of Sodium Chloride Injection). Specific timing applies to certain uses; for instance, administration for biliary duct visualization occurs at least 45 minutes prior to surgery. The drug is used as a single dose per procedure and is not part of a long-term or cyclical regimen. In cases requiring measurement of liver function, the injection is performed while the patient is in a fasting state.

Recent Clinical Evidence Overview

Clinical research on [Drug Name] (Вердай, vorasidenib is a plausible name based on search) has focused primarily on its potential use in specific types of low-grade gliomas that carry an IDH1/2 mutation. This compound is studied as a targeted inhibitor of the isocitrate dehydrogenase (IDH) enzymes.

Key Phase 3 Trial Findings

Results supporting the use of the drug are largely drawn from a pivotal Phase 3 randomized controlled trial (RCT). This global study involved adult participants with residual or recurrent Grade 2 IDH-mutant glioma who had received surgery as their only prior treatment.

Efficacy Results

Outcome Measure	Study Finding (Versus Placebo)
Progression-Free Survival (PFS)	Research examined a delay in disease progression or the need for further therapeutic intervention.
Time to Next Treatment	Studies evaluated a longer interval before the requirement for chemotherapy or radiation therapy.

The study reported changes in both primary and secondary endpoints for the active treatment group compared to the placebo group, suggesting a role in disease management for this patient subset.

Safety and Tolerability

The most commonly documented adverse events in the trials included fatigue, headache, diarrhea, musculoskeletal pain, and increased liver enzyme levels in the blood. Safety monitoring focused particularly on changes in hepatic function (liver health) throughout the long-term trial period. Participation in the trials required specific monitoring of these factors.

Common questions about Вердай (FAQ)

Q: Can I take pain relievers like ibuprofen with Вердай?

A: Official documents and clinical trial information suggest that some non-prescription pain relievers, such as acetaminophen and ibuprofen, are often permitted for use up to certain daily limits. However, the official drug label provides general warnings regarding the potential for drug-drug interactions. The decision to use any medication should be discussed with a healthcare provider.

Q: Does alcohol consumption interact with Вердай?

A: The official information notes a need for caution regarding alcohol consumption while using Вердай. This is because both alcohol and the medicine may cause similar adverse effects, such as headaches, diarrhea, and potential changes in liver enzyme levels. The combination may increase these overlapping risks.

Q: How long after stopping Вердай will it be out of my system?

A: The clearance of this medicine from the body begins quickly, with the drug reaching consistent levels in the body after about 28 days of regular use. The full elimination process typically requires a period equivalent to approximately five half-lives. Information regarding clearance time specific to an individual's health status is typically provided by a healthcare provider.

Q: Does taking Вердай affect my ability to drive or operate machinery?

A: Official drug safety information lists common adverse reactions such as fatigue (tiredness) and dizziness, which could potentially impair a person's ability to drive or use machinery safely. Although the product information states this is generally unlikely to stop normal activities, individuals who experience these side effects should be aware of their potential impact on activities like driving or operating machinery.

Q: Can I crush or split the Вердай tablet?

A: According to the official product information, the tablets must be swallowed whole with water and should not be split, crushed, or chewed. The instruction to swallow the tablet whole is based on the lack of data confirming correct absorption if the tablet is altered.

Q: What happens if I forget to take a dose of Вердай?

A: Regulatory guidance for this medicine states that if a dose is missed, it should be taken as soon as possible, but only if it is within 6 hours of the regular time. If more than 6 hours have passed since the usual time, the product label describes skipping the missed dose and taking the next dose at the regularly scheduled time.

Q: Does Вердай affect blood pressure?

A: Official documents for some products referred to as Вердай list hypotension, which means low blood pressure, as a common adverse reaction from clinical trials. However, some other official labels for different formulations do not list blood pressure changes as a frequent side effect. Information regarding blood pressure concerns is best addressed by a healthcare provider.

Q: Can Вердай interact with herbal remedies, such as St. John's wort?

A: Official patient information and clinical trial exclusion criteria specifically warn that St. John's wort, and certain other herbal supplements, may interact with the medicine. Information regarding the concurrent use of herbal or non-prescription products is typically reviewed by a healthcare professional.

Q: What if I accidentally took two doses of Вердай?

A: Regulatory guidance for a missed dose is to skip it if it is too late, which indicates that doubling a dose is not recommended. The patient information sheet describes contacting a local poison control center or emergency medical care in the event of a suspected overdose.

Q: Can I take Вердай with my daily vitamins or supplements?

A: Official patient instructions specifically warn against taking certain non-prescription or herbal products, such as St. John's wort, due to known interaction risks. While general daily vitamins are not typically listed, the prescribing information has general warnings for interactions. Reviewing all supplements with a healthcare team can help manage potential interaction risks.

Q: Do I need a special diet while taking Вердай?

A: The drug is to be taken on an empty stomach, which involves a specific time interval around dosing when food consumption is limited. Additionally, official information notes that eating grapefruit and drinking grapefruit juice should be discussed with a healthcare professional.

Q: What are the most common mild side effects of Вердай?

A: The most common adverse reactions reported in clinical trials, occurring in 15% or more of participants, included fatigue (tiredness), headache, musculoskeletal pain, diarrhea, and nausea. These events were reported to be low-grade in clinical studies, but the experience and severity of any side effect can vary for each individual.

Q: Can Вердай affect my sleep?

A: The official adverse reaction lists frequently include symptoms such as fatigue and headache, which are known to be able to interfere indirectly with normal sleep patterns. While sleep disturbance itself is not listed as a primary, frequent side effect, persistent changes to sleep are typically reviewed with a healthcare provider.

Q: Do I need to take Вердай at the same time every day?

A: Regulatory information describes taking the tablets once daily at about the same time each day. Taking the medicine at a consistent time helps maintain steady and predictable levels of the drug in the body, which is noted as important for its effectiveness.

Q: How is Вердай usually started and stopped?

A: Treatment is usually started based on the patient's body weight and health status following surgery, using specific regulatory guidelines. The process for discontinuation is managed by the treating physician and typically occurs if the disease progresses or if the patient experiences unacceptable side effects. There are specific guidelines for dose modification based on changes in liver enzyme levels.

Q: Does Вердай affect mood or personality?

A: The official safety profiles primarily list physical and metabolic side effects. However, the patient information describes contacting a healthcare professional if there are signs of electrolyte problems, such as hyperkalemia, as these may include symptoms like confusion or changes in mood.

Q: Is there a maximum time someone can stay on Вердай?

A: According to the official documents, treatment should be continued for as long as a clinical benefit is observed or until the patient cannot tolerate the treatment. This means there is no fixed, predefined maximum duration of treatment established in the regulatory information.

Q: When was Вердай first approved for use?

A: The drug, or a closely related version, received its first regulatory approval from the U.S. Food and Drug Administration (FDA) on August 6, 2024. This approval was specifically granted for a type of Grade 2 glioma with IDH1/2 mutations.

Q: Can Вердай be used by children?

A: The medicine is approved for use in pediatric patients who are 12 years of age and older and who meet the specific diagnostic criteria. Official safety and effectiveness studies have not been established for pediatric patients who are less than 12 years of age.

Q: What is the typical duration of treatment with Вердай?

A: There is no specified typical duration of treatment for this medicine. Treatment is continued until either the disease progresses or the patient experiences side effects that require stopping the medication. The pivotal clinical trial that supported its approval had a median follow-up time of approximately 14 months.

Q: What should I do if I experience a side effect that is not listed?

A: Official guidance describes contacting a healthcare team, including a doctor, nurse, or pharmacist, for management and proper reporting of any side effects, even those that are not explicitly listed in the patient handout.

Q: Are there any known genetic factors that influence how Вердай works?

A: The drug is a targeted therapy that works by inhibiting the IDH1 and IDH2 enzymes. It is only approved for use in tumors that have a susceptible mutation in the IDH1 or IDH2 gene. This required genetic mutation status is the primary factor that dictates how the medicine will function.

Q: Are there any common foods that interact with Вердай?

A: Official patient information specifically notes that eating grapefruit and drinking grapefruit juice should be discussed with a healthcare professional. These items are known to potentially interact with certain medications and could affect how the medicine works in the body.

The storage and disposal instructions for Вердай (Indocyanine Green) are governed by strict regulatory rules, particularly concerning the product's instability after mixing.

Official Storage and Stability

Product Form	Storage Requirement
Unreconstituted Powder	Store at a Controlled Room Temperature of 20 to 25 C (68 to 77 F).
Reconstituted Solution	The solution is unstable and must be used within 6 hours after it is prepared.

Preparation must be performed using sterile/aseptic techniques. The solution must be visually inspected after reconstitution; if a precipitate is present, the solution must be discarded.

Disposal Requirements

Any solution remaining unused after the mandatory 6-hour time limit must be discarded. The product is supplied in a single-patient-use vial, requiring that all residual contents be discarded after use. Used needles and syringes must be disposed of immediately in an FDA-cleared sharps disposal container.